This year saw the approval of new highly effective direct-acting antiviral therapies for hepatitis C, with more in the pipeline and due for approval in 2017.
This year saw the approval of new highly effective direct-acting antiviral therapies for hepatitis C, with more in the pipeline and due for approval in 2017.